BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/9/2022 12:48:14 PM | Browse: 230 | Download: 824
 |
Received |
|
2022-01-18 04:30 |
|
Peer-Review Started |
|
2022-01-18 04:31 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-03-10 06:48 |
|
Revised |
|
2022-03-23 09:38 |
|
Second Decision |
|
2022-08-04 02:57 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-08-05 21:41 |
|
Articles in Press |
|
2022-08-05 21:41 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-08-03 00:41 |
|
Typeset the Manuscript |
|
2022-08-30 13:39 |
|
Publish the Manuscript Online |
|
2022-09-09 12:48 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
Potential of six-transmembrane epithelial antigen of the prostate 4 as a prognostic marker for colorectal cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ze-Xuan Fang, Chun-Lan Li, Wen-Jia Chen, Hua-Tao Wu and Jing Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81501539 |
| Natural Science Foundation of Guangdong Province |
2021A1515012180, 2016A030312008 |
| Special Grant for Key Area Programs of Guangdong Department of Education |
2021ZDZX2004 |
| Science and Technology Special Project of Guangdong Province |
210715216902829 |
| “Dengfeng Project” for the Construction of High-level Hospitals in Guangdong Province-First Affiliated Hospital of Shantou University College Supporting Funding |
202003-10 |
|
| Corresponding Author |
Jing Liu, MD, PhD, Academic Research, Associate Professor, Research Scientist, Senior Scientist, Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Breast Cancer, Cancer Hospital of Shantou University Medical College, No. 22 Xinling Road, Shantou 515041, Guangdong Province, China. jliu12@stu.edu.cn |
| Key Words |
Six-transmembrane epithelial antigen of the prostate; Colorectal cancer; Immunotherapy; Target; Survival |
| Core Tip |
This study analyzed the expression levels of six-transmembrane epithelial antigen of the prostate (STEAP) family members in colorectal cancer (CRC) and explored the potential biological function of STEAP4. It was found that the expression of STEAP4 in CRC tissues had a positive correlation with immune infiltration and immune-related biomarkers, such as MLH1, MLH6, and PMS2, and a negative correlation with programmed death ligand 1. STEAP4 is expected to be a novel and potential prognostic biomarker for CRC. |
| Publish Date |
2022-09-09 12:48 |
| Citation |
Fang ZX, Li CL, Chen WJ, Wu HT, Liu J. Potential of six-transmembrane epithelial antigen of the prostate 4 as a prognostic marker for colorectal cancer. World J Gastrointest Oncol 2022; 14(9): 1675-1688 |
| URL |
https://www.wjgnet.com/1948-5204/full/v14/i9/1675.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v14.i9.1675 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
